EIDOS runs on UbiOps
Hot off the press!
Working with the Netherlands Cancer Institute, Ellogon.AI has developed a faster and more efficient method of determining whether a cancer patient may benefit from immunotherapy.
The tool used for this, EIDOS, is based on big data and artificial intelligence (AI) and runs on UbiOps!
”On average, 45 out of 100 cancer patients are selected for immunotherapy. Only 15 of them actually benefit. This is regrettable, because it is an expensive therapy. What is even more important is that people who would have benefitted are currently not selected. We use AI to make that selection process more accurate.” @Robert Kuipers (CEO at Ellogon.AI) explains.
UbiOps is extremely proud to contribute to such valuable projects!
Both English and Dutch versions of the article available:
KWF grant together with Amsterdam UMC, NKI and UvA
KWF grant together with Amster…
European Network of AI Excellence Centres (ELISE) 1st open call
Interview of co-founder Efstra…
WeakSTIL: Weak whole-slide image level stromal tumor infiltrating lymphocyte scores are all you need
Scientific publication by Yoni…
KWF grant together with Amsterdam UMC, NKI and UvA12 January 2023
KWF grant together with Amsterdam UMC, NKI and UvA 12 January 2023 Jessica We are happy to announce that Ellogon.AI has received a KWF grant together with the Amsterdam UMC,…
European Network of AI Excellence Centres (ELISE) 1st open call8 August 2022
Interview of co-founder Efstratios Gavves by ELISE
WeakSTIL: Weak whole-slide image level stromal tumor infiltrating lymphocyte scores are all you need4 April 2022
Scientific publication by Yoni Schirris, PhD student of the HISTO-AI project.